Human Vaccines

World Market Report

MCP-1176

EXECUTIVE ENGAGEMENTS

POOL

5519
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

883
Interactions with Platform & by Email

PARTICIPANTS

166
Unique # Participated

VALIDATIONS

36
Responses Validated*

COMPANIES

16
Responses Validated*
* Login for a full stack data experience

DATE

JAN 2022

TABLES

202

PAGES

262

EDITION

16

PRICE

USD 5600

CODE

MCP-1176


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

STRONG ACTIVE NICHE TRIVIAL

%

VALIDATED RESEARCH *

S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What's New for 2022?

» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year

Amid the COVID-19 crisis, the global market for Human Vaccines estimated at US$44.2 Billion in the year 2020, is projected to reach a revised size of US$80.3 Billion by 2027, growing at a CAGR of 8.9% over the analysis period 2020-2027. Intramuscular & Subcutaneous, one of the segments analyzed in the report, is projected to record a 9.4% CAGR and reach US$65.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Oral segment is readjusted to a revised 7% CAGR for the next 7-year period.
The Human Vaccines market in the U.S. is estimated at US$11.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$18.8 Billion by the year 2027 trailing a CAGR of 13.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.
In the global Other Administration Routes segment, USA, Canada, Japan, China and Europe will drive the 5.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2.6 Billion in the year 2020 will reach a projected size of US$3.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$11.2 Billion by the year 2027, while Latin America will expand at a 7.7% CAGR through the analysis period.

SELECT PLAYERS

ALK - Abelló A/S; Altimmune, Inc.; Astellas Pharma Inc.; Bavarian Nordic A/S; Bharat Biotech; BiondVax Pharmaceuticals Ltd.; GlaxoSmithKline Plc; Hualan Biological Engineering Inc.; Janssen Pharmaceuticals Inc.; MedImmune; Mitsubishi Tanabe Pharma; Pfizer Inc.; Sanofi Pasteur SA; Seqirus; Serum Institute of India Pvt. Ltd.; SK BioScience; Takeda Pharmaceutical Company Limited; Zydus Cadila

SEGMENTS

» Administration Route (Intramuscular & Subcutaneous, Oral, Other Administration Routes) » Technology (Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated, Other Technologies)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Human Vaccines: A Prelude
Recent Market Activity
Competitive Scenario
Vaccine Pricing: A Review
Human Vaccines – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
ALK - Abelló A/S (Denmark)
Altimmune, Inc. (USA)
Astellas Pharma Inc. (Tokyo)
Bavarian Nordic (Denmark)
BiondVax Pharmaceuticals Ltd. (Israel)
Bharat Biotech (India)
GlaxoSmithKline Plc. (UK)
Hualan Biological Engineering Inc. (China)
Janssen Pharmaceuticals, Inc. (USA)
MedImmune (USA)
Merck Sharp & Dohme Corp., (USA)
Mitsubishi Tanabe Pharma Corporate (Japan)
Pfizer, Inc. (USA)
Sanofi Pasteur SA (France)
Serum Institute of India Pvt. Ltd. (India)
Seqirus (UK)
SK BioScience (Korea)
Takeda Pharmaceutical Company Limited (Japan)
Zydus Cadila (India)
3. MARKET TRENDS & DRIVERS
Combination Vaccines Market Driven by Fast Expanding Pediatric Population
List of Combination Vaccines in the US: 2018
Gardasil 9 Offers Protection against HPV for Expanded Age Group
Increasing Demand for Recombinant Vaccines
Global Cholera Vaccines Market
Further Clinical Trials Needed for an Effective Zika Vaccine
Merck’s rVSV-ZEBOV Ebola Vaccine used for Ring Vaccination in Congo
Rising Dengue Cases Drive Vaccines Demand
Sanofi’s Dengue Vaccine First-to-Market
EMA Recommends Approval of Dengue Vaccine
Vaccine for AIDS
Staggering Global Statistics of AIDS - Opportunity Indicator
Toxoid Vaccines Market
H1N1 Vaccines Market
HSV Vaccine on the Horizon
Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market
BCG Vaccines
Key TB Vaccine Candidates in the Pipeline: 2018
New Vaccine for Herpes Zoster or Shingles
Two-dose Hepatitis B Vaccine for Adults
Global Rotavirus Vaccines Market
Typhoid Vaccines Market
Measles Vaccines Market
DNA Vaccines: Engineering Growth
Mobile Money Encourages Parents for Vaccinating Children
Noninjectable Vaccines: Gain without Pain
Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines
Novel Technologies Ensure Timely Vaccine Delivery for Patients in Remote Locations
Smart mRNA Vaccines
Growing Pricing Pressure - A Major Market Deterrent
Safety Issues Come to the Fore
Novel Vaccination Guidelines Mitigate Risks Associated with Developing Shoulder Injuries
BioWarfare: Threat Perception and Preparedness
Overview of Potential Bio-Terrorist Agents
Smallpox (Variola Major)
Anthrax (Bacillus Anthracis)
Plague (Yersinia Pestis)
Botulism (Clostridium Botulinum)
Tularemia (Francisella Tularensis)
Tackling Cold Chain Issues
Trade Statistics
Growing Incidence of Infectious Diseases Drives the Global Human Vaccines Market
Total Number of Infectious Disease Covered under Vaccination
Conjugate Vaccines Rule in Human Vaccines Market
Pneumococcal Vaccines – A Major Segment
Vaccine Pipeline by Major Companies
GSK Vaccine Pipeline
Merck Vaccines Pipeline
Pfizer Vaccines Pipeline
Sanofi Vaccines Portfolio
Emergent BioSolutions Inc. - Vaccine Pipeline
Astellas Pharma - Vaccines
Pediatric Vaccines Dominate the Human Vaccines Market
Select Pediatric Vaccines
Adults Vaccine Market to Witness Rapid Growth, Driven by Government Initiatives
Select Adult Vaccines
Developed Markets Dominate, Emerging Regions to Exhibit the Fastest Growth
Pneumococcal Vaccines Market Set to Witness Rapid Growth
Influenza Vaccines Market: A High Growth Segment
Cancer Vaccines Market Offers Potential Opportunities
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Intramuscular & Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Intramuscular & Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Intramuscular & Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Inactivated & Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Inactivated & Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Inactivated & Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Live Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
UNITED STATES
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
USA Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
CANADA
Canada Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
JAPAN
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Japan Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
CHINA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
China Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
EUROPE
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Europe Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
FRANCE
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
France Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
GERMANY
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Germany Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
ITALY
Italy Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
UNITED KINGDOM
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
UK Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
SPAIN
Spain Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Spain Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
RUSSIA
Russia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Russia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
AUSTRALIA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
Australia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Australia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
INDIA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
India Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
India Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
India Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
India Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
SOUTH KOREA
South Korea Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
South Korea Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
LATIN AMERICA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
Latin America Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Latin America Historic Review for Human Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027
Latin America Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Latin America Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
ARGENTINA
Argentina Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Argentina Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
BRAZIL
Brazil Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Brazil Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
MEXICO
Mexico Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Mexico Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
REST OF LATIN AMERICA
Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
MIDDLE EAST
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
Middle East Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Middle East Historic Review for Human Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027
Middle East Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Middle East Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
IRAN
Iran Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Iran Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
ISRAEL
Israel Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Israel Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
SAUDI ARABIA
Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
UNITED ARAB EMIRATES
UAE Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
UAE Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
REST OF MIDDLE EAST
Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
AFRICA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
Africa Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2012, 2021 & 2027
Africa Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2012, 2021 & 2027
Total Companies Profiled: 16

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com